TY - JOUR AU - Tan, Emily L.C. AU - Ooi, Eng Eong AU - Lin, Chin-Yo AU - Tan, Hwee Cheng AU - Ling, Ai Ee AU - Lim, Bing AU - Stanton, Lawrence W. T1 - Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs T2 - Emerging Infectious Disease journal PY - 2004 VL - 10 IS - 4 SP - 581 SN - 1080-6059 AB - Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti–SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, β-1b, α-n1, α-n3, and human leukocyte interferon α. These findings support clinical testing of approved interferons for the treatment of SARS. KW - In vitro KW - antivirals KW - agents KW - antiviral KW - antiviral agents KW - antiviral drugs KW - SARS virus KW - severe acute respiratory syndrome KW - coronavirus infection DO - 10.3201/eid1004.030458 UR - https://wwwnc.cdc.gov/eid/article/10/4/03-0458_article ER - End of Reference